Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 3Recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 4NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Neoplasms 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1

Interventions

Specimen Handling 115Magnetic Resonance Spectroscopy 77Biopsy 69Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 14Disulfides 14X-Rays 13Radiation 13Doxorubicin 12venetoclax 11Radiotherapy 11Gemcitabine 11durvalumab 9cabozantinib 8aldesleukin 8Prednisone 8atezolizumab 7Cytarabine 7olaparib 6lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NIH × Hyaluronoglucosaminidase × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡